{"log_id": 4898598196540861237, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 9e-06, "average": 0.996633, "min": 0.992341}, "location": {"width": 157, "top": 178, "height": 34, "left": 272}, "words": "【儿童用药】"}, {"probability": {"variance": 0.007728, "average": 0.961983, "min": 0.66731}, "location": {"width": 713, "top": 230, "height": 36, "left": 336}, "words": "18岁以下的患者用本品的安全性和有效性尚未经研究确定"}, {"probability": {"variance": 4e-06, "average": 0.998435, "min": 0.993797}, "location": {"width": 157, "top": 288, "height": 34, "left": 272}, "words": "【老年用药】"}, {"probability": {"variance": 0.018989, "average": 0.947602, "min": 0.370979}, "location": {"width": 1134, "top": 338, "height": 43, "left": 329}, "words": "据文献报道:帕洛谱司琼在1374名成年癌症患者的临床研究中,其中316(23%)例≥65"}, {"probability": {"variance": 0.005394, "average": 0.964311, "min": 0.570986}, "location": {"width": 1207, "top": 393, "height": 43, "left": 265}, "words": "岁,71例(5%)≥75岁。除某些老年个体较为敏感以外,帕洛诺司琼用于老年患者与年轻患者"}, {"probability": {"variance": 0.001994, "average": 0.982823, "min": 0.796171}, "location": {"width": 1079, "top": 452, "height": 38, "left": 265}, "words": "在安全性和有效性方面无差别。因此,老年患者用帕洛诺司琼无需调整剂量和特殊监护"}, {"probability": {"variance": 3.4e-05, "average": 0.994722, "min": 0.98471}, "location": {"width": 217, "top": 512, "height": 34, "left": 276}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.003265, "average": 0.976894, "min": 0.789207}, "location": {"width": 1143, "top": 564, "height": 38, "left": 326}, "words": "帕洛诺司琼的体内消除途径包括经肾分泌及多种CYP酶参与的。体外进一步研究表明,帕洛"}, {"probability": {"variance": 0.010889, "average": 0.949494, "min": 0.395184}, "location": {"width": 1191, "top": 621, "height": 36, "left": 269}, "words": "诺司琼既不是CYP1A2、CYP2.A6、CYP236、CYP2C9CYP2D6、CYP2I和CYP3M/5(CYP2C19未研究"}, {"probability": {"variance": 0.016434, "average": 0.933962, "min": 0.499896}, "location": {"width": 1202, "top": 676, "height": 38, "left": 269}, "words": "的抑制剂,也不诱导 CYPIA2、CYP206或CYP3A4/5的活性,因此,与帕洛诺可琼产生明显的临床"}, {"probability": {"variance": 0.004986, "average": 0.976858, "min": 0.742898}, "location": {"width": 347, "top": 736, "height": 36, "left": 269}, "words": "药物相互作用的可能性很低"}, {"probability": {"variance": 0.008109, "average": 0.959112, "min": 0.570199}, "location": {"width": 1143, "top": 791, "height": 38, "left": 329}, "words": "使康志愿者同时静脉注射0.25mg帕洛诺司琼和20mg地塞米松后,没有出现两种药物间药代"}, {"probability": {"variance": 0.000239, "average": 0.993738, "min": 0.907686}, "location": {"width": 1198, "top": 848, "height": 36, "left": 272}, "words": "动力学上的相互作用。另一项在健康志愿者上进行的药物相互作用的临床试验表明,第一日静脉"}, {"probability": {"variance": 0.017431, "average": 0.936154, "min": 0.35254}, "location": {"width": 1202, "top": 903, "height": 36, "left": 269}, "words": "注射0.25ng帕洛诺司琼,同时连续三天口服(125m/80mg/8mg)阿瑞匹坦,对洛诺司琼药代"}, {"probability": {"variance": 0.019912, "average": 0.942674, "min": 0.359127}, "location": {"width": 724, "top": 960, "height": 34, "left": 274}, "words": "动力学没有显著改变(AUC:没有改变,Cx:升高15%)"}, {"probability": {"variance": 0.009629, "average": 0.94934, "min": 0.61112}, "location": {"width": 1145, "top": 1012, "height": 36, "left": 329}, "words": "健康志愿者单剂静脉给予0.75mg的帕洛诺司琼,稳定期口服胃复安(每天四次:每次10mg)"}, {"probability": {"variance": 7.7e-05, "average": 0.994141, "min": 0.970781}, "location": {"width": 486, "top": 1069, "height": 36, "left": 272}, "words": "的研究中未发现明显的药代动力学影响"}, {"probability": {"variance": 0.003292, "average": 0.976964, "min": 0.664404}, "location": {"width": 1145, "top": 1127, "height": 36, "left": 331}, "words": "临床研究表明,帕洛诺司琼能安全地与皮质类固醇类、镇痛药、止吐药、解痉药和抗胆碱能"}, {"probability": {"variance": 0.000139, "average": 0.993631, "min": 0.967361}, "location": {"width": 171, "top": 1184, "height": 32, "left": 274}, "words": "药物一起应用"}, {"probability": {"variance": 0.018397, "average": 0.927768, "min": 0.490555}, "location": {"width": 1143, "top": 1236, "height": 34, "left": 333}, "words": "鼠肿瘤模型研究表明,帕洛诺司琼不会抑制所研究的五种化疗药物(顶铂、环磷酰胺、阿糖"}, {"probability": {"variance": 0.031943, "average": 0.903365, "min": 0.488832}, "location": {"width": 509, "top": 1291, "height": 36, "left": 274}, "words": "胞苷、阿霉崇和丝裂霉素C)的抗癌活性"}, {"probability": {"variance": 0.014559, "average": 0.923282, "min": 0.687715}, "location": {"width": 155, "top": 1348, "height": 34, "left": 285}, "words": "【药物过量"}, {"probability": {"variance": 0.01266, "average": 0.950679, "min": 0.456884}, "location": {"width": 1147, "top": 1406, "height": 36, "left": 331}, "words": "尚无已知的帕洛诺司琼的解毒剂,因此药物过量时应该用支持疗法。在帕洛诺司琼剂探索"}, {"probability": {"variance": 0.016382, "average": 0.943387, "min": 0.35774}, "location": {"width": 1198, "top": 1460, "height": 38, "left": 274}, "words": "研究中,50名成人癌症患者给予90μg/kg的剂相当6mg的固定剂量),接近推荐剂量0.25mg"}, {"probability": {"variance": 0.023185, "average": 0.929635, "min": 0.41378}, "location": {"width": 1202, "top": 1513, "height": 50, "left": 276}, "words": "的25倍。该剂量组产生的不良反应事件与银相见量依赖性:尽管未进行过透析"}, {"probability": {"variance": 0.015688, "average": 0.951673, "min": 0.4009}, "location": {"width": 1202, "top": 1570, "height": 38, "left": 276}, "words": "治疗的研究,但是由于帕洛诺司苏具有大的布容积透析不可能作为有效的治疗药物过量"}, {"probability": {"variance": 0.022203, "average": 0.916866, "min": 0.512763}, "location": {"width": 1202, "top": 1627, "height": 36, "left": 276}, "words": "手段。大鼠和小鼠单剂量静脉给予帕洛的致死量为30g7g(按体表面积换算,大鼠和小鼠"}, {"probability": {"variance": 0.034126, "average": 0.901545, "min": 0.352009}, "location": {"width": 1188, "top": 1678, "height": 43, "left": 276}, "words": "的剂量分别相当于人体推荐剂量的94744倍),主要中症状为惊、喘息、肤苍白、发绀"}, {"probability": {"variance": 0.000283, "average": 0.982213, "min": 0.965395}, "location": {"width": 61, "top": 1742, "height": 32, "left": 278}, "words": "虚脱"}, {"probability": {"variance": 0.000259, "average": 0.986619, "min": 0.963127}, "location": {"width": 157, "top": 1794, "height": 34, "left": 288}, "words": "【临床试验】"}, {"probability": {"variance": 0.000673, "average": 0.986699, "min": 0.904454}, "location": {"width": 429, "top": 1849, "height": 34, "left": 336}, "words": "以下数据主要来白于国外研究文献"}, {"probability": {"variance": 0.024716, "average": 0.937962, "min": 0.413037}, "location": {"width": 1140, "top": 1904, "height": 36, "left": 338}, "words": "在三项I期临床研究和一个I期临床研究中,分别评价了帕洛诺司琼单剂注射剂预防中"}, {"probability": {"variance": 0.00689, "average": 0.972498, "min": 0.490556}, "location": {"width": 1198, "top": 1957, "height": 36, "left": 281}, "words": "度和重度致吐化疗导致的急性和延迟性恶心呕吐的治疗效果;在这些双盲临未研究中,评价化疗"}, {"probability": {"variance": 0.006128, "average": 0.973314, "min": 0.539388}, "location": {"width": 1195, "top": 2011, "height": 36, "left": 281}, "words": "后至少120hr的完全缓解率(无呕吐发作和不需药物治疗〕和其它疗效参数:以及进行重复化疗"}], "language": 3}